Compare Stocks: TXG, PACB, MTD, and MEDP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MEDP Medpace	$593.39 +0.1%	$573.38	$373.00 ▼ $677.90	$16.55B	1.15	200,238 shs	143,229 shs
MTD Mettler-Toledo International	$1,357.19 -0.8%	$1,360.01	$1,023.05 ▼ $1,525.17	$27.40B	1.22	169,326 shs	168,344 shs
PACB Pacific Biosciences of California	$1.30 -1.5%	$1.41	$1.07 ▼ $2.73	$410.30M	2.31	7.63 million shs	5.14 million shs
TXG 10x Genomics	$63.22 +2.5%	$50.40	$11.16 ▼ $66.94	$8.03B	2.08	3.17 million shs	2.17 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MEDP Medpace	+0.06%	-2.97%	+3.18%	+30.63%	+23.31%
MTD Mettler-Toledo International	-0.73%	-3.55%	-5.56%	+17.61%	+7.10%
PACB Pacific Biosciences of California	-1.52%	-16.13%	-9.72%	-10.34%	+3.17%
TXG 10x Genomics	+2.55%	-2.51%	+32.09%	+103.67%	+373.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MEDP Medpace	$593.39 +0.1%	$573.38	$373.00 ▼ $677.90	$16.55B	1.15	200,238 shs	143,229 shs
MTD Mettler-Toledo International	$1,357.19 -0.8%	$1,360.01	$1,023.05 ▼ $1,525.17	$27.40B	1.22	169,326 shs	168,344 shs
PACB Pacific Biosciences of California	$1.30 -1.5%	$1.41	$1.07 ▼ $2.73	$410.30M	2.31	7.63 million shs	5.14 million shs
TXG 10x Genomics	$63.22 +2.5%	$50.40	$11.16 ▼ $66.94	$8.03B	2.08	3.17 million shs	2.17 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MEDP Medpace	+0.06%	-2.97%	+3.18%	+30.63%	+23.31%
MTD Mettler-Toledo International	-0.73%	-3.55%	-5.56%	+17.61%	+7.10%
PACB Pacific Biosciences of California	-1.52%	-16.13%	-9.72%	-10.34%	+3.17%
TXG 10x Genomics	+2.55%	-2.51%	+32.09%	+103.67%	+373.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MEDP Medpace	2.25	Hold	$595.20	0.31% Upside
MTD Mettler-Toledo International	2.33	Hold	$1,445.31	6.49% Upside
PACB Pacific Biosciences of California	1.80	Reduce	$1.83	41.03% Upside
TXG 10x Genomics	2.24	Hold	$40.57	-35.83% Downside

Current Analyst Ratings Breakdown

Latest TXG, PACB, MTD, and MEDP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	MTD Mettler-Toledo International	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell	$1,200.00
9/1/2026	TXG 10x Genomics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$70.00
9/1/2026	MTD Mettler-Toledo International	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$1,515.00
9/1/2026	TXG 10x Genomics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sector Perform	$70.00
8/25/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	MEDP Medpace	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/12/2026	TXG 10x Genomics	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$50.00 ➝ $65.00
8/11/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	TXG 10x Genomics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$42.00 ➝ $47.00
8/10/2026	TXG 10x Genomics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $60.00
8/7/2026	TXG 10x Genomics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$37.00 ➝ $40.00

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MEDP Medpace	$2.53B	6.55	$17.03 per share	34.85	$15.54 per share	38.18
MTD Mettler-Toledo International	$4.03B	6.75	$49.24 per share	27.56	$0.64 per share	2,120.61
PACB Pacific Biosciences of California	$160.01M	2.53	$0.78 per share	1.67	($0.11) per share	-11.82
TXG 10x Genomics	$642.82M	12.81	N/A	N/A	$6.34 per share	9.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MEDP Medpace	$451.12M	$17.06	34.78	30.95	2.65	17.67%	110.15%	24.84%	10/28/2026 (Estimated)
MTD Mettler-Toledo International	$869.19M	$44.43	30.55	25.96	2.81	21.91%	-1,212.14%	25.11%	11/5/2026 (Estimated)
PACB Pacific Biosciences of California	-$546.38M	-$0.43	N/A	N/A	N/A	-82.49%	-5,752.12%	-19.52%	11/3/2026 (Estimated)
TXG 10x Genomics	-$43.54M	-$0.59	N/A	N/A	N/A	-12.18%	-9.33%	-7.30%	11/5/2026 (Estimated)

Latest TXG, PACB, MTD, and MEDP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	TXG 10x Genomics	-$0.2431	-$0.14	+$0.1031	-$0.14	$146.67 million	$151.04 million
8/3/2026	Q2 2026	PACB Pacific Biosciences of California	-$0.1280	-$0.14	-$0.0120	-$0.14	$42.90 million	$39.01 million
7/31/2026	Q2 2026	MTD Mettler-Toledo International	$10.78	$11.46	+$0.68	$11.55	$1.03 billion	$1.03 billion
7/22/2026	Q2 2026	MEDP Medpace	$3.98	$4.25	+$0.27	$4.25	$689.51 million	$707.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MEDP Medpace	N/A	N/A	N/A	N/A	N/A
MTD Mettler-Toledo International	N/A	N/A	N/A	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A
TXG 10x Genomics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MEDP Medpace	N/A	0.73	0.73
MTD Mettler-Toledo International	159.45	1.12	0.78
PACB Pacific Biosciences of California	N/A	4.92	4.03
TXG 10x Genomics	N/A	5.69	5.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MEDP Medpace	77.98%
MTD Mettler-Toledo International	95.07%
PACB Pacific Biosciences of California	N/A
TXG 10x Genomics	84.68%

Insider Ownership

Company	Insider Ownership
MEDP Medpace	20.50%
MTD Mettler-Toledo International	0.71%
PACB Pacific Biosciences of California	3.70%
TXG 10x Genomics	8.84%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MEDP Medpace	6,200	27.91 million	22.19 million	Optionable
MTD Mettler-Toledo International	18,100	20.04 million	19.90 million	Optionable
PACB Pacific Biosciences of California	730	310.83 million	299.33 million	Optionable
TXG 10x Genomics	1,240	130.29 million	118.77 million	Optionable

TXG, PACB, MTD, and MEDP Headlines

Recent News About These Companies

10x Genomics (NASDAQ:TXG) Research Coverage Started at Royal Bank Of Canada

September 4 at 1:36 AM | americanbankingnews.com

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

September 3 at 2:56 PM | zacks.com

RBC Capital initiates coverage of 10x Genomics (TXG) with sector perform recommendation

September 2 at 1:18 PM | msn.com

Royal Bank Of Canada Upgrades 10x Genomics (NASDAQ:TXG) to "Hold"

September 2 at 7:35 AM | marketbeat.com

Proficio Capital Partners LLC Takes $781,000 Position in 10x Genomics $TXG

September 2 at 5:28 AM | marketbeat.com

10x Genomics Needs "Meaningful' Growth in Single-Cell Business, RBC Says

September 1 at 2:49 PM | finance.yahoo.com

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

August 31, 2026 | zacks.com

Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit

August 31, 2026 | benzinga.com

10x Genomics (NASDAQ:TXG) CEO Serge Saxonov Sells 10,486 Shares

August 29, 2026 | insidertrades.com

North Star Asset Management Inc. Invests $988,000 in 10x Genomics $TXG

August 29, 2026 | marketbeat.com

Insider Selling: 10x Genomics (NASDAQ:TXG) CEO Sells $667,853.34 in Stock

August 28, 2026 | marketbeat.com

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

August 28, 2026 | prnewswire.com

10x Genomics (NASDAQ:TXG) Director Sells 2,207 Shares of Stock

August 27, 2026 | insidertrades.com

10x Genomics CEO Serge Saxonov Sells 18,545 Shares to Cover RSU Tax Withholding

August 27, 2026 | kalkinemedia.comK

10x Genomics (NASDAQ:TXG) Director Shehnaaz Suliman Sells 2,207 Shares of Stock

August 26, 2026 | marketbeat.com

Insider Selling: 10x Genomics (NASDAQ:TXG) Insider Sells 13,818 Shares of Stock

August 26, 2026 | marketbeat.com

Adam Taich Sells 17,166 Shares of 10x Genomics (NASDAQ:TXG) Stock

August 26, 2026 | marketbeat.com

10x Genomics (NASDAQ:TXG) CEO Serge Saxonov Sells 18,545 Shares

August 26, 2026 | marketbeat.com

10x Genomics (NASDAQ:TXG) Sets New 12-Month High - Time to Buy?

August 25, 2026 | marketbeat.com

10x Genomics (NASDAQ:TXG) Receives Average Rating of "Hold" from Brokerages

August 23, 2026 | marketbeat.com

10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)

August 20, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG, PACB, MTD, and MEDP Company Descriptions

Medpace NASDAQ:MEDP

$593.39 +0.37 (+0.06%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$595.84 +2.45 (+0.41%)

As of 09:04 AM Eastern

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Mettler-Toledo International NYSE:MTD

$1,357.19 -10.55 (-0.77%)

Closing price 09/3/2026 03:58 PM Eastern

Extended Trading

$1,356.80 -0.38 (-0.03%)

As of 09:04 AM Eastern

Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, density and refractometry, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection equipment, x-ray systems, check weighing equipment, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of weighing and software solutions, AI-driven image recognition solution, and automated packaging and labelling solutions for the meat backroom. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is based in Columbus, Ohio.

Pacific Biosciences of California NASDAQ:PACB

$1.30 -0.02 (-1.52%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.33 +0.03 (+2.00%)

As of 09:10 AM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

10x Genomics NASDAQ:TXG

$63.22 +1.57 (+2.55%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$62.63 -0.59 (-0.93%)

As of 09:15 AM Eastern

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TXG, PACB, MTD, and MEDP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TXG, PACB, MTD, and MEDP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TXG, PACB, MTD, and MEDP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG, PACB, MTD, and MEDP Company Descriptions

Medpace NASDAQ:MEDP

Mettler-Toledo International NYSE:MTD

Pacific Biosciences of California NASDAQ:PACB

10x Genomics NASDAQ:TXG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TXG, PACB, MTD, and MEDP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TXG, PACB, MTD, and MEDP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TXG, PACB, MTD, and MEDP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG, PACB, MTD, and MEDP Company Descriptions

Medpace NASDAQ:MEDP

Mettler-Toledo International NYSE:MTD

Pacific Biosciences of California NASDAQ:PACB

10x Genomics NASDAQ:TXG

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools